These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 10530514)

  • 1. Polymorphisms of the human apolipoprotein E promoter and bleomycin hydrolase gene: risk factors for Alzheimer's dementia?
    Thome J; Gewirtz JC; Sakai N; Zachariou V; Retz-Junginger P; Retz W; Duman RS; Rösler M
    Neurosci Lett; 1999 Oct; 274(1):37-40. PubMed ID: 10530514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The -491A/T apolipoprotein E promoter polymorphism association with Alzheimer's disease: independent risk and linkage disequilibrium with the known APOE polymorphism.
    Town T; Paris D; Fallin D; Duara R; Barker W; Gold M; Crawford F; Mullan M
    Neurosci Lett; 1998 Aug; 252(2):95-8. PubMed ID: 9756330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Promoter polymorphism (-491A/T) in the APOE gene of Finnish Alzheimer's disease patients and control individuals.
    Helisalmi S; Hiltunen M; Valonen P; Mannermaa A; Koivisto AM; Lehtovirta M; Ryynänen M; Soininen H
    J Neurol; 1999 Sep; 246(9):821-4. PubMed ID: 10525981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymorphisms in the apolipoprotein E (APOE) gene in gerontopsychiatric patients.
    Zill P; Engel R; Hampel H; Behrens S; Bürger K; Padberg F; Stübner S; Möller HJ; Ackenheil M; Bondy B
    Eur Arch Psychiatry Clin Neurosci; 2001; 251(1):24-8. PubMed ID: 11315514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apolipoprotein E promoter polymorphisms (-491A/T and -427T/C) and Alzheimer's disease: no evidence of association in the Irish population.
    Lynch CA; Brazil J; Cullen B; Coakley D; Gill M; Lawlor BA; Hawi Z
    Ir J Med Sci; 2008 Mar; 177(1):29-33. PubMed ID: 18057979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ApoE -491A/T promoter polymorphism is not an independent risk factor, but associated with the epsilon4 allele in Hungarian Alzheimer's dementia population.
    Juhász A; Palotás A; Janka Z; Rimanóczy A; Palotás M; Bódi N; Boda K; Zana M; Vincze G; Kálmán J
    Neurochem Res; 2005 May; 30(5):591-6. PubMed ID: 16176061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Haplogroup analysis of the risk associated with APOE promoter polymorphisms (-219T/G, -491A/T and -427T/C) in Colombian Alzheimer's disease patients.
    Parra-Bonilla G; Arboleda G; Yunis J; Solano E; Pardo R; Arango G; Hedmont D; Arboleda H
    Neurosci Lett; 2003 Oct; 349(3):159-62. PubMed ID: 12951193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apolipoprotein E promoter polymorphisms and risk of Alzheimer's disease: evidence from meta-analysis.
    Xin XY; Ding JQ; Chen SD
    J Alzheimers Dis; 2010; 19(4):1283-94. PubMed ID: 20061606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of association between bleomycin hydrolase and apolipoprotein E polymorphism in Alzheimer's disease.
    Smach MA; Charfeddine B; Lammouchi T; Othman LB; Letaief A; Nafati S; Dridi H; Bennamou S; Limem K
    Neurol Sci; 2010 Dec; 31(6):687-91. PubMed ID: 20198498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. APOE-epsilon4 and APOE -491A polymorphisms in individuals with subjective memory loss.
    Laws SM; Clarnette RM; Taddei K; Martins G; Paton A; Hallmayer J; Almeida OP; Groth DM; Gandy SE; Förstl H; Martins RN
    Mol Psychiatry; 2002; 7(7):768-75. PubMed ID: 12192621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. APOE promoter polymorphisms do not confer independent risk for Alzheimer's disease in a French population.
    Zurutuza L; Verpillat P; Raux G; Hannequin D; Puel M; Belliard S; Michon A; Pothin Y; Camuzat A; Penet C; Martin C; Brice A; Campion D; Clerget-Darpoux F; Frebourg T
    Eur J Hum Genet; 2000 Sep; 8(9):713-6. PubMed ID: 10980578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of the APOE-491A/T promoter polymorphism on apolipoprotein E levels and risk of Alzheimer disease: The Rotterdam Study.
    Roks G; Cruts M; Houwing-Duistermaat JJ; Dermaut B; Serneels S; Havekes LM; Hofman A; Breteler MM; Van Broeckhoven C; van Duijn CM
    Am J Med Genet; 2002 Jul; 114(5):570-3. PubMed ID: 12116196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The algorithm for Alzheimer risk assessment based on APOE promoter polymorphisms.
    Limon-Sztencel A; Lipska-Ziętkiewicz BS; Chmara M; Wasag B; Bidzan L; Godlewska BR; Limon J
    Alzheimers Res Ther; 2016 May; 8(1):19. PubMed ID: 27193889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between bleomycin hydrolase and Alzheimer's disease in caucasians.
    Farrer LA; Abraham CR; Haines JL; Rogaeva EA; Song Y; McGraw WT; Brindle N; Premkumar S; Scott WK; Yamaoka LH; Saunders AM; Roses AD; Auerbach SA; Sorbi S; Duara R; Pericak-Vance MA; St George-Hyslop PH
    Ann Neurol; 1998 Nov; 44(5):808-11. PubMed ID: 9818937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of APOE genotype and promoter polymorphism on risk of Alzheimer's disease.
    Wang JC; Kwon JM; Shah P; Morris JC; Goate A
    Neurology; 2000 Dec; 55(11):1644-9. PubMed ID: 11113217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of APOE promoter but not A2M polymorphisms with risk of developing Alzheimer's disease.
    Halimi G; Duplan L; Bideau C; Iniesta D; Berthézène P; Oddoze C; Verdier JM; Michel B; Bergé-Lefranc JL
    Neuroreport; 2000 Nov; 11(16):3599-601. PubMed ID: 11095526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A polymorphism in the regulatory region of APOE associated with risk for Alzheimer's dementia.
    Bullido MJ; Artiga MJ; Recuero M; Sastre I; García MA; Aldudo J; Lendon C; Han SW; Morris JC; Frank A; Vázquez J; Goate A; Valdivieso F
    Nat Genet; 1998 Jan; 18(1):69-71. PubMed ID: 9425904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Apolipoprotein E and bleomycin hydrolase. Polymorphisms: association with neurodegenerative diseases].
    Nivet-Antoine V; Coulhon MP; Le Denmat C; Hamon B; Dulcire X; Lefebvre M; Piette F; Davous P; Durand D; Duchassaing D
    Ann Biol Clin (Paris); 2003; 61(1):61-7. PubMed ID: 12604387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. APOE and APOC1 promoter polymorphisms and the risk of Alzheimer disease in African American and Caribbean Hispanic individuals.
    Tycko B; Lee JH; Ciappa A; Saxena A; Li CM; Feng L; Arriaga A; Stern Y; Lantigua R; Shachter N; Mayeux R
    Arch Neurol; 2004 Sep; 61(9):1434-9. PubMed ID: 15364690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High expression of apolipoprotein E mRNA in the brains with sporadic Alzheimer's disease.
    Yamagata K; Urakami K; Ikeda K; Ji Y; Adachi Y; Arai H; Sasaki H; Sato K; Nakashima K
    Dement Geriatr Cogn Disord; 2001; 12(2):57-62. PubMed ID: 11173875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.